Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Nuvo Pharmaceuticals Inc MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. see more

OTCQX:MRVFF - Post Discussion

Nuvo Pharmaceuticals Inc > Good leverage
View:
Post by lscfa on Mar 08, 2021 8:03pm

Good leverage

If cash flow is used to pay down debt and the low multiple stays the same stock price doubles.

 

2021 ebitda 

22.6

22.6

x Multiple

6.0

6.0

= Ent value

135.6

135.6

- Net debt

115.6

94.0

 = Mkt cap

20.0

41.6

/ Shs o/s

11.4

11.4

= Share value

$1.75

$3.65

Comment by Marathon11 on Mar 08, 2021 8:56pm
What are your thoughts on the 25M+ warrants and the $40M prospectus and the fact that only BB covers this? I'm still acquiring.
Comment by lscfa on Mar 08, 2021 11:53pm
The warrants have a $3.53 exercise price and won't be exercised any time soon. The $40 million prospectus has a 2 year shelf life and suggests they want to be ready in case an acquistion presents itself.    
Comment by ronz on Mar 09, 2021 8:41am
Shouldn't they be addressing the debt first from their last acquistion? Their business model isn't great. Their only option appears to start printing shares.... Sounds a lot more like the old Nuvo and Dimethaid business model again. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities